Approved HBV Drugs
Approved HBV Drugs
Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults
- Details
- Category: HBV Treatment
- Published on Thursday, 30 August 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) this week announced that product label information for tenofovir (Viread) has been revised to include further information about treatment of chronic hepatitis B in teenagers and 240-week data for adult patients. 
EASL 2012: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Large Study Finds Tenofovir Linked to Increased Kidney Risk
- Details
- Category: Liver, Kidney & Bone Toxicity
- Published on Friday, 10 February 2012 00:00
- Written by Liz Highleyman
HIV positive people who took tenofovir (Viread, also in the Truvada and Atripla combination pills) were more likely to show signs of impaired kidney function, according to an observational study of more than 10,000 people described in the February 4, 2012, advance online edition of AIDS.
EASL 2012: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.
Web Design and Development by